- $67.90m
- -$49.31m
- $0.80m
Brief: Ikena Oncology And Vall D'hebron Institute Of Oncology Announce R&D Collaboration
Brief: Ikena Oncology To Present At The American Society Of Clinical Oncology Annual Meeting
Brief: Ikena Oncology Files For Mixed Shelf Of Up To $300 Mln
Brief: Ikena Appoints Jotin Marango As CFO And Head Of Corporate Development
Brief: Ikena Oncology Inc Says In April 2022, Co Advanced To Stage Two Of Nivolumab Combination Expansion Cohort In Phase 1B Clinical Trial Of Ik-175
U.S. RESEARCH ROUNDUP-Digitalbridge Group, Joann, Park Ohio Holdings
Ikena Oncology Inc reports results for the quarter ended in December - Earnings Summary
Brief: Ikena Oncology Reports Q4, Full Year 2021 Financial Results
Brief: Ikena Oncology Says Board Increase Size Of Board From Seven To Eight Directors
Brief: Ikena Appoints Richard Wooster To Its Board Of Directors
Brief: Ikena Oncology Presents Data Describing Indication Selection Methodology, Translational Data, Trial In Progress For IK-175
Ikena Oncology Inc reports results for the quarter ended in September - Earnings Summary
Brief: Ikena Oncology Reports Third Quarter 2021 Financial Results
Brief: Ikena Oncology Announces FDA Acceptance Of IND Application Of Novel TEAD Inhibitor IK-930
Brief: Ikena Oncology Presents Data At Aacr-Nci-Eortc Virtual Conference Demonstrating Potential Of Tead Inhibitors In Cancer Treatment
U.S. RESEARCH ROUNDUP- Abcellera Biologics, Linde, Spire
Ikena Oncology Inc reports results for the quarter ended in June - Earnings Summary
Brief: Ikena Oncology Reports Second Quarter 2021 Financial Results And Provides Update On Key Programs
Ikena Oncology Inc expected to post a loss of 36 cents a share - Earnings Preview